Kingsoft Cloud (NASDAQ:KC – Get Free Report) and Portage Biotech (NASDAQ:ALP – Get Free Report) are both technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Insider and Institutional Ownership
13.4% of Kingsoft Cloud shares are owned by institutional investors. Comparatively, 13.4% of Portage Biotech shares are owned by institutional investors. 14.2% of Kingsoft Cloud shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Kingsoft Cloud has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Earnings and Valuation
This table compares Kingsoft Cloud and Portage Biotech”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kingsoft Cloud | $11.02 billion | 0.23 | -$84.59 million | ($0.28) | -30.50 |
| Portage Biotech | $97,000.00 | 51.61 | -$633.95 million | ($409.00) | -0.01 |
Kingsoft Cloud has higher revenue and earnings than Portage Biotech. Kingsoft Cloud is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Kingsoft Cloud and Portage Biotech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kingsoft Cloud | 1 | 0 | 4 | 1 | 2.83 |
| Portage Biotech | 1 | 2 | 0 | 0 | 1.67 |
Kingsoft Cloud currently has a consensus price target of $16.67, suggesting a potential upside of 95.16%. Portage Biotech has a consensus price target of $12.50, suggesting a potential upside of 287.00%. Given Portage Biotech’s higher possible upside, analysts plainly believe Portage Biotech is more favorable than Kingsoft Cloud.
Profitability
This table compares Kingsoft Cloud and Portage Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kingsoft Cloud | N/A | N/A | N/A |
| Portage Biotech | N/A | N/A | N/A |
Summary
Kingsoft Cloud beats Portage Biotech on 9 of the 12 factors compared between the two stocks.
About Kingsoft Cloud
Kingsoft Cloud Holdings Limited provides cloud services to businesses and organizations primarily in China. The company's products portfolio includes cloud products, including infrastructure as a service (IaaS) infrastructure, platform as a service (PaaS) middleware, and software as a service (SaaS) applications that primarily consist of cloud computing, network, database, big data, security, storage, and delivery solutions. It offers research and development services, as well as enterprise digital solutions and related services. The company also provides public cloud services to customers in various verticals, including video, e-commerce, intelligent mobility, artificial intelligence, and mobile internet; and enterprise cloud services to customers in financial services, public service, and healthcare businesses. Kingsoft Cloud Holdings Limited was incorporated in 2012 and is headquartered in Beijing, the People's Republic of China.
About Portage Biotech
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Receive News & Ratings for Kingsoft Cloud Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kingsoft Cloud and related companies with MarketBeat.com's FREE daily email newsletter.
